ST Segment Elevation Myocardial Infarction

0
Pipeline Programs
4
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Sanofi
SanofiPARIS, France
1 program
China STEMI-PCI ProgramN/A
Abbott
AbbottABBOTT PARK, IL
1 program
China STEMI-PCI ProgramN/A1 trial
Active Trials
NCT01716884Unknown4,000Est. Jun 2016
City Therapeutics
City TherapeuticsMA - Cambridge
1 program
Nitroprusside SodiumN/A1 trial
Active Trials
NCT03406819UnknownEst. Dec 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
City TherapeuticsNitroprusside Sodium
AbbottChina STEMI-PCI Program

Clinical Trials (2)

Total enrollment: 4,000 patients across 2 trials

NCT03406819City TherapeuticsNitroprusside Sodium

Prevention of Coronary Slow Flow or No-Reflow During PPCI in Patients With Acute STEMI

Start: Jan 2018Est. completion: Dec 2019
N/AUnknown
NCT01716884AbbottChina STEMI-PCI Program

China STEMI-PCI Program

Start: Dec 2011Est. completion: Jun 20164,000 patients
N/AUnknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 companies competing in this space